Amphastar Pharmaceuticals (AMPH) Asset Writedowns and Impairment (2013 - 2016)

Amphastar Pharmaceuticals has reported Asset Writedowns and Impairment for 4 years, with the latest figure at $114000.0 in Q2 2016.

• On a quarterly basis, Asset Writedowns and Impairment changed N/A year-over-year to $114000.0 in Q2 2016; TTM through Dec 2023 was $114000.0, a N/A change from a year earlier, with the FY2023 full-year figure at $2.7 million, changed N/A from the prior year.
• Asset Writedowns and Impairment was $114000.0 for Q2 2016 at Amphastar Pharmaceuticals, down from $217000.0 in the prior quarter.
• The five-year high for Asset Writedowns and Impairment was $217000.0 in Q1 2016, with the low at $4000.0 in Q3 2015.
• Average Asset Writedowns and Impairment over 4 years is $113555.6, with a median of $120000.0 recorded in 2013.
• The largest YoY upside for Asset Writedowns and Impairment was 64.1% in 2015 against a maximum downside of 69.23% in 2015.
• Over 4 years, Asset Writedowns and Impairment stood at $120000.0 in 2013, then plunged by 35.0% to $78000.0 in 2014, then jumped by 64.1% to $128000.0 in 2015, then fell by 10.94% to $114000.0 in 2016.
• The last three Asset Writedowns and Impairment figures came in at $114000.0 (Q2 2016), $217000.0 (Q1 2016), and $128000.0 (Q4 2015), per Business Quant data.